UroGen Pharma Reports Strong Revenue Growth Driven by Zosturi Sales
UroGen Pharma (NASDAQ: URGN) has demonstrated significant commercial momentum following the FDA approval of its bladder cancer treatment, Zosturi. The company reported quarterly total revenue of $89.0 million, a substantial increase from $27.5 million in the previous year. This growth was primarily driven by Zosturi, which generated $68.0 million in quarterly net product revenue, up 35% from the prior quarter. The company's financial health is improving as its net loss shrank to $1.5 million, down from $33.3 million a year ago, with management projecting profitability in the fourth quarter. Market adoption appears robust; unique prescribers increased to 662, and repeat prescribers now account for approximately 50% of total writers. This indicates that physicians are integrating the gel-based mitomycin delivery system into their standard practice.
Tickers: $URGN
Topics: bladder cancer treatment cash position product performance quarterly revenue
Read the full article at Motley Fool
Part of the story UroGen Pharma Reports Strong Revenue Growth Driven by Zosturi Sales (7 articles)